Overview
Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant (also called left-dominant arrhythmogenic cardiomyopathy or ALVC) is a rare genetic heart condition. In this disease, the normal heart muscle is gradually replaced by fatty or scar tissue, primarily affecting the left ventricle — the heart's main pumping chamber. This replacement of healthy tissue weakens the heart's ability to pump blood effectively and disrupts the electrical signals that keep the heart beating in a regular rhythm. The most common symptoms include irregular heartbeats (arrhythmias), palpitations, dizziness, fainting episodes, shortness of breath, and reduced exercise tolerance. In some cases, the first sign of the disease can be a dangerous heart rhythm disturbance, which is why early detection is so important. The condition typically becomes apparent in adolescence or adulthood, though the age of onset can vary. Treatment focuses on managing symptoms and preventing life-threatening arrhythmias. This may include medications such as beta-blockers or antiarrhythmic drugs, implantable cardioverter-defibrillators (ICDs) to correct dangerous heart rhythms, and in advanced cases, heart transplantation. Exercise restriction is commonly recommended because intense physical activity can worsen the disease. Genetic testing and regular cardiac screening of family members are important parts of managing this condition, since it runs in families.
Also known as:
Key symptoms:
Irregular heartbeat or palpitationsFainting or near-fainting episodesShortness of breath, especially during exerciseChest painDizziness or lightheadednessReduced ability to exerciseFatigue and low energySwelling in the legs or anklesHeart failure symptomsSudden cardiac arrest in severe casesFluttering sensation in the chest
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
3 eventsLexeo Therapeutics
Hamilton Health Sciences Corporation — PHASE2
Lexeo Therapeutics — PHASE1, PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant.
3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Specialists
View all specialists →No specialists are currently listed for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant.
Community
No community posts yet. Be the first to share your experience with Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant.
Start the conversation →Latest news about Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
1 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What is my specific genetic mutation, and what does it mean for my prognosis?,Do I need an implantable defibrillator (ICD), and what are the benefits and risks?,What types and levels of physical activity are safe for me?,Should my family members be tested, and how should screening be done?,How often do I need follow-up imaging and heart rhythm monitoring?,What symptoms should prompt me to seek emergency care immediately?,Are there any clinical trials or new treatments I should know about?
Common questions about Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
What is Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant?
Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant (also called left-dominant arrhythmogenic cardiomyopathy or ALVC) is a rare genetic heart condition. In this disease, the normal heart muscle is gradually replaced by fatty or scar tissue, primarily affecting the left ventricle — the heart's main pumping chamber. This replacement of healthy tissue weakens the heart's ability to pump blood effectively and disrupts the electrical signals that keep the heart beating in a regular rhythm. The most common symptoms include irregular heartbeats (arrhythmias), palpitations, dizzin
How is Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant inherited?
Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Are there clinical trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant?
Yes — 3 recruiting clinical trials are currently listed for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.